Epidemiology Of Lung Cancer Research Articles

Lessons Learned from the Epidemiology of Colorectal, Lung, and Stomach Cancer

Lessons Learned from the Epidemiology of Colorectal, Lung, and Stomach Cancer

Gender Disparities in Their Effects on Characteristics and Prognostics of Lung Cancer Patients in Pulmonary Ward of Dr. M Djamil Hospital, Padang

Background: Lung cancer incidence in female tends to increase in many countries. Various studies have reported the characteristics of lung cancer in female are different from male. The purpose of this study was to determine the effect of gender on characteristics of lung cancer at Dr. M Djamil Hospital, Padang.Methods: A retrospective analytic study of lung cancer patients treated in the Pulmonary Ward of Dr. M. Djamil Hospital Padang from January 1, 2004 to December 31, 2017, with recognized cancer cell types. Data were grouped according to gender.Results: This study found that 451 lung cancer patients, male-dominant 77.8%. Female were younger than male (52.97 ± 12.79 years vs. 57.81 ± 11.23 years; p = 0.00). Most of male (94.5%) were smokers and former smokers, while 93.9% of female were non-smokers (p = 0.00). Most female were having prior history of tuberculosis (TB) (21.2% vs 11.0%; p = 0.008) and also prior history of other organs cancer (10.1% vs 3.4%; p = 0.007) than in male. Squamous cells were highest in males (41.1%), while females had adenocarcinoma (55.0%); with p = 0.008. Advanced stage in female more than male (91.8% vs 82.7%; p = 0.027). The mean life expectancy of female was longer than male, respectively 8.74 ± 1.56 and 7.29 ± 0.64 months; (p = 0.95). Conclusion: There are differences in the epidemiology of lung cancer between male and female in Dr. M. Djamil Hospital Padang in the form of age, cell type and staging. Non-smokers, a previous history of TB and a history of cancer in other organs were more dominant in female.

OA06.04 Constructing a Global Molecular Database for Thoracic Malignancies: The IASLC Molecular Subcommittee Lung Cancer Dataset

Biomarker-directed treatment and prognostication are changing lung cancer care. Differences in the prevalence, and disparities in use, of biomarkers inhibit dissemination of personalized cancer care on a global scale. For the first time, the IASLC’s Staging and Prognostic Factors Committee (SPFC) is accumulating molecular biomarker data to complement TNM-based prognostication. We provide a snapshot below. We collected lung cancer cases diagnosed from 2010 to 2019, staged by 8th edition TNM, from consenting institutions. We describe data sources, NSCLC characteristics and biomarker data (ALK, BRAF, EGFR, KRAS, ROS1, MET, RET, NTRK1, ERBB2 or PD-L1) submitted by Electronic Data Capture (EDC). We compared EDC cases with and without biomarker data as of April 1, 2021. Of 64,434 cases in the SPFC NSCLC database, 6611 (10%) were EDC cases (Figure), of which 2068 (31%) had biomarker data. Almost all cases were submitted from Asia, Australia, North America and Europe (Table). All biomarker data came from 14 countries, including China (28%), Canada (25%), Spain (15%), Australia (10%), and India (5%). Cases with biomarker data were more likely to be adenocarcinoma, advanced stage and non-surgical, although 46% had had surgery. Single gene tests predominated, EGFR (70%) was most common. Most cases were wildtype, ranging from 68% of KRAS to 100% of NTRK tested cases (Table).Tabled 1VariableBiomarker Data Not Available, N= 4543Biomarker Data Available, N - 2068PAge, years (%) <65 ≥652129 (46) 2414 (53)1113 (53) 955 (46)< 0.001Female Sex (%)1890 (41)853 (41)0.79Continent (%) Asia/Australia North America Europe South/Central America Africa/Middle East1373 (30) 1645 (36) 1239 (27) 266 (5) 20 (0)1014 (49) 586 (28) 444 (21) 23 (1) 1 (0)<0.001Histology (%) Adenocarcinoma Squamous NSCLC NOS Adenosquamous Large cell neuroendocrine2889 (36) 1352 (29) 94 (2) 79 (1) 34 (0)1573 (76) 355 (17) 90 (4) 27 (1) 12 (0)<0.001Aggregate clinical stage (%) 0 – IB IIA – IIIB IIIC – IVB2642 (61) 1264 (29) 420 (9)549 (27) 623 (30) 844 (41)<0.001Aggregate pathologic stage (%) 0 – IB IIA – IIIB IIIC – IVB2224 (63) 1169 (33) 125 (3)407 (44) 447 (49) 55 (6)<0.001Treatment (%) Surgery Chemotherapy Immunotherapy Radiation therapy3626 (82) 1268 (30) 73 (2) 642 (15)945 (46) 983 (52) 291 (15) 424 (22)<0.001Genomic data available: Tested (%); percentage wildtypeALK BRAF EGFR KRAS ROS-1 MET RET NTRK ERBB2291 (14); 92% 139 (6); 88% 1461 (70); 77% 306 (14); 68% 176 (8); 88% 78 (3); 90% 31 (1); 94% 24 (1); 100% 73 (3); 92%PDL1 tested (%) Percentage with Tumor Proportion Score: >50% 1-50%1237 (59) 15% 21% Open table in a new tab Most of the EDC cases with biomarker data are from a few institutions in Asia, Australia, Europe and North America. This database will expand as we include non-EDC cases. However, given the potential for a global database to create insights into patterns and outcomes of lung cancer care, a more comprehensive recruitment of additional institutions, countries and continents is needed, to ensure that the dataset reflects the global epidemiology of lung cancer. We will analyze the full SPFC data sample in future reports.

Significant Regional Differences in Lung Cancer Incidence in Hungary: Epidemiological Study Between 2011 and 2016.

Objective: Hungary has one of the highest incidences and mortality rates of lung cancer (LC), therefore the objective of this study was to analyse and compare LC incidence and mortality rates between the main Hungarian regions.Methods: This nationwide, retrospective study used data from the National Health Insurance Fund and included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between Jan 1, 2011 and Dec 31, 2016. Age-standardized incidence and mortality rates were calculated and compared for the main regions.Results: The highest incidence rate in males was recorded in Northern Hungary (146.8/100,000 person-years [PY]), while the lowest rate was found in Western Transdanubia (94.7/100,000 PY in 2011). All rates showed a declining trend between 2011 and 2016, with the largest decrease in the Northern Great Plain (−20.0%; p = 0.008). LC incidence and mortality rates in women both showed a rising tendency in all regions of Hungary, reaching the highest in Central Hungary (59.86/100,000 PY in 2016). Lung cancer incidence and mortality rates in males correlated with the level of education and smoking prevalence (p = 0.006 and p = 0.01, respectively) in the regions. A correlation with GDP per capita and Health Development Index (HDI) index could also be observed in the Hungarian regions, although these associations were not statistically significant. No correlations could be detected between these parameters among females.Conclusion: This analysis revealed considerable differences in the epidemiology of LC between the 7 main Hungarian regions. LC incidence and mortality rates significantly correlated with smoking and certain socioeconomic factors in men, but not in women. Further research is needed to explain the regional differences.

Epidemiology of lung cancer in Eastern India with focus on histopathological subtypes and smoking history: a single rural tertiary center experience

Background: Lung cancer is the most common cancer and the leading cause of mortality worldwide. Smoking remains the commonest risk factor for development of lung cancer. This study aimed to evaluate the histopathological subtypes and smoking history among patients with lung cancer.Methods: This was a retrospective observational study that included all the patients attending Radiotherapy OPD of Burdwan Medical College during 2017 and 2018. Demographic data, smoking history, comorbidities, symptoms, smoking history, histology of lung cancer, stage at presentation, site of metastasis, and site of lesions were collected.Results: There were 484 patients, with a median age of 59 years, of which 82.4% were men and 17.6% were women. The men-to-women ratio was 4.7:1. Regular smoking was common in patients with lung cancer (72.7%). Total 12.4% of patients had small-cell carcinoma; of the 87.6% patients with non-small-cell carcinoma, the most common histology was adenocarcinoma (44.6%), followed by squamous cell (38.4%), large cell (17.0%). The most common metastatic sites were lung (42.1%) followed by bone (34.1%), lymph node (15.9%), liver (2.7%), vertebra (2.5%), pleura (2.1%), and anterior chest wall (0.6%). A larger proportion of men (92.6%) were smokers as compared women. There was a statistically higher occurrence of adenocarcinoma in smokers than in non-smokers (62.2% vs. 2.4%; p&lt;0.001). The majority of patients with a smoking history (73.0%) were found to have advanced cancer (Stage IV).Conclusions: The present study confirmed that apart from smoking history, demographic characteristics appear to have an impact on lung cancer development.

Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis.

BackgroundTo describe the incidence and the clinical characteristics of oligometastatic non-small cell lung cancer (NSCLC) patients. Oligometastatic NSCLC is gaining recognition as a clinical condition with a different prognosis compared to multi metastatic disease. Usually, four different scenarios of oligometastatic disease can be described but not epidemiological data are available. To date, it is difficult to delineate an exhaustive epidemiological scenario because no uniform or shared definition of oligometastatic status exists, even though a recent consensus defined synchronous oligometastatic disease as having a maximum of 5 metastases in 3 different organs.MethodsA systematic review and a pooled analysis of literature were performed. Article selection was based on the following characteristics: focus on lung cancers; dealing with oligometastatic settings and providing a definition of oligometastatic disease; number of metastatic lesions with or without the number of organs involved; providing some incidence or clinical characteristics of oligometastatic NSCLC patients. Series focusing on a specific single metastatic organ were excluded. The research was launched in MEDLINE (OvidSP) in March 2020. Full articles were individually and collectively read by the authors according to the previous criteria. Each author inspected the reference list included in the eligible articles. If the selection criteria were recognized, the article was reviewed by all authors and then included. Data on patient clinical features were pooled together from 31 articles selected.ResultsA total number of 31 articles have been selected for the analysis. The following variables were extracted from the publications: (I) number of metastases, (II) number of organs involved, (III) number of patients, (IV) number and percentage of males and females, (V) number and percentage of squamous and non-squamous histology, (VI) T and N status and/or stage of primary disease for oligometastatic setting. The data collected have been analyzed according to the oligometastatic setting.ConclusionsOligometastatic status is globally identified as a different clinical condition from multi metastatic NSCLC, although the clinical characteristics were consistent in the general metastatic population, even with a lower-than-expected TN status. The brain and bones were the most frequent organs involved. Lacking consensus definition, these results must be interpreted cautiously and a prospective evaluation is urgently needed.

Lung cancer - dia nosis and early detection.

Decisions about the treatment of a patient with lung cancer depend on the clinical stage of the disease, morphological diagnosis, examination of predictive markers and overall clinical condition; the wishes of a well-informed patient must also be taken into account. Accurate diagnosis is essential for the future of a patient with lung cancer. The epidemiology of lung cancer is related to cigarette consumption. The risk of the disease increases with the number of cigarettes smoked. The relative risk for smokers is 22.4, for very heavy smokers with a load of more than 25 packets, it can reach up to 50. Most cases of lung cancer are caught in the advanced stages of the disease, when surgery and sometimes other active treatments are no longer possible. Searching for lung cancer in at-risk groups is essential for reducing lung cancer mortality, leading to the detection of the disease at a low stage when the tumor is operable.

Demographical differentials of lung cancer survival in Bangladeshi patients.

10570 Background: Lung Cancer is the leading cause of cancer-related mortality and most common cancer in worldwide with more than a million deaths annually. 20.8% cancer related death caused by lung cancer and more than half of lung cancer occurred in Asia. Differences In the epidemiology of lung cancer among the developing country may shed light on possible genetic and demographical influences on lung cancer survival. Demographic stratification of lung cancer patients of Bangladesh is remain unclear due of lack of data We tried to figure out the demographic pattern and its impact on survival in Bangladeshi lung cancer patient. Methods: Previously diagnosed primary lung cancer patients attending Medical Oncology department of National Institute of cancer research and Hospital, a tertiary care center of Bangladesh, between 2018 and 2019 were included. Demographic and clinical data were collected retrospectively from the medical records. Results: A total of 1868 consecutive patient (1580 males, 288females) diagnosed to have lung cancer; Mean age was 60 years which quite early compare to other countries. Older than 70-year age groups had worse survival outcome (hazard ratio 1.04: 95% confidence interval: 1.17–1.68). Below 50-year group had better outcome with standard adjuvant or palliative chemotherapy whereas older groups had better survival with sequential radiotherapy and chemotherapy or concurrent chemo radiation (Hazard Ratio 0.45; 95% confidence interval: 0.30–0.67). Sex was not a predicting factor for overall survival (Hazard ratios 1.04 95% confidence interval 0.89- 1.22, P = 0.621). But, Male had better treatment response than the female (Hazard ratio and 95% confidence interval: 0.51 and 0.42-0.61, P = &lt; 0.001). Education level had significant impact on survival outcome (Hazard ratio 0.58 and 95% confidence interval: 0.47-0.71, P = &lt; 0.001). Underweight group had worse survival than the normal BMI group (Hazard ratio1.18 and 95% confidence interval 1.05-1.31, P = 0.005). Having the Comorbid condition at the time of diagnosis had shorter survival (Hazard ratio 1.16 and 95% confidence interval 1.04-1.30 P = 0.007). Histological variation had no survival benefit among the squamous, small cell or other histological types (p = 0.214, 0.494, 0.658 respectively). But adenocarcinoma or small cell carcinoma had better treatment response outcome. Eastern Cooperative Oncology Group performance status (ECOG-PS) 4 had worse outcome (Hazard ratio 1.95, 95% confidence interval 1.37–2.79; P = &lt; 0.001). Conclusions: The socio-demographic related survival in lung cancer needs to be fully elucidated because of its implication in the design of experimental protocols for targeted chemoprevention, early disease screening, molecular marker based staging, and individualized treatment. Due to its extraordinary disease burden and the international variability in demographic variables, the lung cancer requires continual monitoring.

Featuring Trends in the Epidemiology of Lung Cancer Following the Publication of the National Cancer Strategy in Qatar.

ObjectivesQatar has witnessed significant reforms in its health care system, including the care of cancer patients. In 2011, the National Cancer Strategy was released with the aim to deliver a high standard of care to cancer patients across the country. We sought to investigate the featuring trends in the epidemiological and clinical characteristics of lung cancer in Qatar following the publication of the National Cancer Strategy.MethodsWe conducted a retrospective cohort study documenting the epidemiological and clinical characteristics of primary lung cancer cases in Qatar diagnosed from 1 January 2011 to 31 December 2018.ResultsThe overall age-standardized incidence rate was 8.7 per 100 000 persons (11.6 per 100 000 and 5.4 per 100 000 persons for males and females, respectively). The one, three, and five-year overall survival rates were 67.0%, 48.0%, and 28.0%, respectively. The three-year overall survival rates for stages I, II, III, and IV were 97.0%, 78.0%, 52.0%, and 31.0%, respectively. The three-year survival rates for males and females were 43.0% and 64.0%, respectively (p = 0.029), for Qatari and non-Qatari nationals were 42.0% and 49.0%, respectively (p = 0.252), and for smokers and non-smokers were 39.0% and 69.0%, respectively (p ≤ 0.001). The overall age-standardized mortality rate was 5.5 per 100 000 persons. Adenocarcinoma was the most common histologic type.ConclusionsDespite the low overall lung cancer incidence rate in Qatar, there is a rise in the incidence among females when compared to previous studies. Qatar has favorable five-year lung cancer survival rates compared to many developed and neighboring countries. Policymakers in the country should consider the changing patterns in lung cancer incidence when planning future preventive strategies.

Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016.

Objective: No assessment was conducted describing the age and gender specific epidemiology of lung cancer (LC) prior to 2018 in Hungary, thus the objective of this study was to appraise the detailed epidemiology of lung cancer (ICD-10 C34) in Hungary based on a retrospective analysis of the National Health Insurance Fund database. Methods: This longitudinal study included patients aged ≥20 years with LC diagnosis (ICD-10 C34) between January 1, 2011 and December 31, 2016. Patients with different cancer-related codes 6 months before or 12 months after LC diagnosis or having any cancer treatment other than lung cancer protocols were excluded. Results: Lung cancer incidence and mortality increased with age, peaking in the 70–79 age group (375.0/100,000 person-years) among males, while at 60–69 age group for females (148.1/100,000 person-years). The male-to-female incidence rate ratio reached 2.46–3.01 (p < 0.0001) among the 70–79 age group. We found 2–11% decrease in male incidence rate at most age groups, while a significant 1–3% increase was observed in older females (>60) annually during the study period. Conclusion: This nationwide epidemiology study demonstrated that LC incidence and mortality in Hungary decreased in younger male and female population, however we found significant increase of incidence in older female population, similar to international trends. Incidence rates peaked in younger age-groups compared to Western countries, most likely due to higher smoking prevalence in these cohorts, while lower age LC incidence could be attributed to higher competing cardiovascular risk resulting in earlier mortality in smoking population.

Epidemiology and histopathological classification of lung cancer: A study from Jordan, retrospective observational study

BackgroundLung cancer is a major health burden in Jordan. With the failure of tobacco control policies and the evolution of new smoking methods like water pipes and e-cigarettes, lung cancer is projected to further increase. This study investigates the epidemiology and the different histopathological subtypes of lung cancer in correlation with age, sex and smoking. Material and methods434 tumors diagnosed in the main tertiary hospital in Northern Jordan throughout the period of 2004–2017 were included. Specimens were tested by H&E and immunohistochemical stains. Clinical data were collected from patients' medical files. IRB approval number 310/2016 was granted by Jordan University of Science and Technology review board. Results86.9% of cases were males compared to 13.1% in females obtaining a male:female ratio of 6.6:1. The mean age was 63.8 years with a range of 28–103 years. Prevalence of cases increased with increasing age and smoking. Histopathologically, adenocarcinoma accounted for over half of the cases followed by Squamous cell carcinoma (SCC) and neuroendocrine tumors (NET) in both sexes. Adenocarcinoma had the lowest mean age; 62.74 years, while SCC had the highest mean age with 65.42 years. All subtypes increased with age but in different degrees. The increase was more pronounced in SCC and NET and less with adenocarcinoma. Adenocarcinoma was more common in both smokers and non-smokers. However, smokers to non-smokers ratio differed; where it was the highest in NET (6:1) compared to 4:1 in SCC and 2:1 in adenocarcinoma. ConclusionMedian age of our patients was slightly lower than that previously reported in Jordan. This study also showed an increase in the relative incidence of adenocarcinoma compared to SCC.

Recent Trends of Lung Cancer in Korea.

Lung cancer is one of the leading causes of cancer-related deaths in Korea. Although the smoking rate has decreased over time, the prevalence of lung cancer still remains high. In this study, we reviewed recent trends on the incidence, epidemiology, screening, diagnosis, and treatment of lung cancer in Korea by analyzing data from the national lung cancer registry and recently-published studies. Although approximately 40% of patients with non–small cell lung cancer (NSCLC) were diagnosed as stage IV, the 5-year relative survival rate improved from 11.3% (1993–1995) to 30.2% (2013–2017), possibly due to advances in methods of diagnosis and therapy. In addition, the 2019 implementation of the national lung cancer screening program with low-dose computed tomography may have also contributed to these improvements in survival rates. Recently, molecular diagnosis has become more widely used in the identification of genetic mutations in tissue specimens. Target therapy and immune checkpoint inhibitors have also been successfully used, particularly in cases of advanced NSCLC. In the future, further research on the optimal management of lung cancer remains necessary.

Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer.

Breast cancer is the most common malignancy in women, and lung cancer, the leading cause of cancer-related mortality in the United States, is the most common subsequent primary cancer among breast cancer survivors. In this review, we examine the risk factors that cause subsequent primary lung cancer after breast cancer (referred to herein as BCLC patients) as well as the prognostic factors that may affect survival. Notable clinicopathological features include patient characteristics such as age, smoking history, and the presence of EGFR or BRCA mutations, as well as factors related to the treatment of breast cancer such as radiation, surgery, chemotherapy, stage, anti-estrogen therapy, and ER/PR/HER2 status.

The molecular basis of gender disparities in smoking lung cancer patients

AimsGender disparities exist in smoking-related lung cancer epidemiology, but the molecular basis has not been explored so far. We aimed at identifying genes with gender-bias expression pattern in smoking lung cancer patients for understanding the molecular basis of gender bias in smokers using meta-analysis of microarray gene expression data. Materials and methodsTranscriptome of around 1100 samples from 13 studies were used in the meta-analysis to identify ‘Lung Cancer genes specific to Female-Smokers’ (LCFS) and ‘Lung Cancer genes specific to Male-Smokers’ (LCMS). The expression profiles of these genes were validated with an independent microarray report and TCGA-RNA-sequencing data. The molecular interactions, pathway, and other functional annotations were portrayed for the key genes identified. Key findingsWe identified 1159 gender-biased genes in smoking lung cancer patients. Of these, 400 and 474 genes showed differential expression in cancerous compared to normal lung of women (LCFS) and men (LCMS), respectively. While many up-regulated LCFS were involved in ‘immune responses’ including T-cell activation, leukocyte cell-cell adhesion, the LCMS were mainly involved in ‘positive regulation of gene expression’, signaling pathways including RAS, VEGF, insulin-receptor signaling, and ‘cell cycle’. SignificanceThe strategic-method identified genes, particularly, SNX20, GIMAP6, MTMR2, FAM171B, IDH1, MOBP, FBXO17, LPXN and WIPF1, which were consistently differentially expressed in at least 4 studies, and in agreement with RNA-Seq data. Exploring their functions could be beneficial to the gender-based diagnosis, prognosis, and treatment of lung cancer in smokers. The current meta-analysis supports existing knowledge of sexual-dimorphism of immune responses in cancer.

Epidemiology of lung cancer in northeast of Iran: A 25-year study of 939 patients

Epidemiology of lung cancer in northeast of Iran: A 25-year study of 939 patients

THREE METACHRONOUS PRIMARY LUNG CANCERS IN A CHRONIC SMOKER: A CASE REPORT

SESSION TITLE: Fellows Lung Cancer Posters SESSION TYPE: Fellow Case Report Posters PRESENTED ON: October 18-21, 2020 INTRODUCTION: Lung cancer is the worldwide leading cause of cancer-related deaths. Patients once treated curatively for lung cancer can develop subsequent primary lung cancer. Smoking is the major risk factor for the development of lung cancer and contributes to a higher risk of developing a second lung cancer in patients who continue to smoke after diagnosis and treatment of the initial cancer. The subsequent primary lung cancer can be treated successfully, however, both treatment regimen and prognosis depend on whether it is synchronous or metachronous. CASE PRESENTATION: A 60-year-old smoker with 55 pack-year history, presented with cough and hemoptysis. His physical exam was remarkable for clubbing. His pulmonary function testing revealed moderately severe chronic obstructive pulmonary disease (COPD). A Computerized Tomographic (CT) scan revealed a right upper lobe spiculated mass. Positron emission tomography (PET) scan showed standard uptake value (SUV) of 4.5 in the primary tumor and ipsilateral hilar and paratracheal nodes in metastatic range. Histopathologic examination of a transthoracic needle biopsy showed poorly differentiated adenocarcinoma (ADC) of the lung, stage IIIA. The patient was curatively treated with chemotherapy and radiation. After nine years he developed a new posterior left upper lobe spiculated nodule. PET/CT showed it to have an SUV of 4. The patient underwent apical wedge resection of the left upper lobe. Histopathological examination showed moderately differentiated keratinizing squamous cell carcinoma (SCC), stage IA1. He was given extensive counseling on smoking cessation, but he was still not able to quit. Six months later, CT of the chest showed increased soft tissue density and adenopathy of the right hilum with perilymphatic nodules in the right upper and lower lobes consistent with lymphangitic carcinomatosis. The patient underwent transbronchial biopsy reporting a small cell carcinoma (SCLC). Due to poor performance status, he was not a candidate for systemic chemotherapy, and he decided to go into hospice care. DISCUSSION: We reviewed the clinical and pathological features of synchronous and metachronous lung cancers in previously described patients. These patients were below the average age at which first lung cancer diagnosis is made in most patients, had long smoking histories, and histological type occurred in random order. The patients with metachronous cancers continued to smoke after the first or second cancer diagnosis which placed them at a higher risk for subsequent cancer(s). CONCLUSIONS: We recommend that patients with lung cancer diagnosis must quit smoking to reduce the risk of a second primary cancer, and those who do not quit should remain on long-term surveillance. Reference #1: de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220-233. Reference #2: Han SS, Rivera GA, Tammemagi MC, et al. Risk Stratification for Second Primary Lung Cancer. J Clin Oncol. 2017;35(25):2893-2899. Reference #3: Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018;68(4):297-316 DISCLOSURES: No relevant relationships by Boris Betancourt, source=Web Response No relevant relationships by Lillian Chow, source=Web Response No relevant relationships by Dushyant Damania, source=Web Response No relevant relationships by Raavi Gupta, source=Web Response no disclosure on file for M Haseeb; no disclosure on file for Absia Jabbar; No relevant relationships by James Mahoney, source=Admin input No relevant relationships by gurinder sidhu, source=Web Response

1233P Epidemiology of female lung cancer in tertiary level hospitals in Bangladesh

1233P Epidemiology of female lung cancer in tertiary level hospitals in Bangladesh

Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian).

BackgroundDifferences in carcinogenesis and therapeutic efficacy according to ethnicity have been reported for lung cancer, and understanding differences in genetic mutation profiles among ethnicities is important for interpreting the results of clinical trials, preventing carcinogenesis, and individualizing treatment. However, no studies have focused on differences in mutation profiles among different ethnicities using large-scale genomic analysis data with detailed information on smoking history, the main cause of lung cancer.MethodsTo clarify the differences in genetic mutation profiles between Caucasian and Japanese subjects, we compared data from The Cancer Genome Atlas, which mainly included Caucasians, with results from the Japan Molecular Epidemiology for lung cancer study, which is an epidemiological study only involving Japanese subjects. We divided the participants into four groups according to smoking status and performed comparative analysis by tissue type (lung adenocarcinoma and squamous cell lung cancer).ResultsIn patients with lung adenocarcinoma, the frequency of EGFR mutations was lower in Caucasian subjects than in Japanese subjects (14.6% vs. 51.1%), whereas the frequencies of mutations in other genes, namely KRAS (32.9% vs. 9.3%), TP53 (45.2% vs. 20.7%), BRAF (9.6% vs. 1.3%), PIK3CA (5.9% vs. 2.6%), KEAP1 (17.8% vs. 0.5%), NF1 (10.9% vs. 0.5%), STK11 (17.8% vs. 0.7%), RBM10 (8.7% vs. 0.1%), and MET (7.8% vs. 0.1%), were higher in Caucasian subjects. Among patients with squamous cell carcinoma, TP53 (81.2% vs. 49.1%), PIK3CA (14.5% vs. 6.8%), KEAP1 (12.7% vs. 0.9%), and NFE2L2 mutations (15.8% vs. 13.6%) were more common in Caucasian subjects.ConclusionsEthnicity is an important and complex characteristic that must be recognized and considered, even in the era of precision medicine. We should collaborate to share data for different ethnicities and incorporate them into clinical practice and the design of global clinical studies. Carefully designed molecular epidemiological studies focusing on ethnic differences are warranted.

The Epidemiology of Lung Cancer in Lebanon During 2014

Background and aims: Lung cancer is the leading cause of cancer death worldwide. There are no recent data on the lung cancer prevalence in Lebanon, and the available data are based on prediction. Thus, this study aimed to determine the incidence rate of lung cancer during 2014, among patients who were newly diagnosed at Lebanese teaching hospitals. In addition, the study attempted to identify the associated risk factors of lung cancer, the most common presenting symptoms at the diagnosis time, and the stage at which the majority of the patients were diagnosed at the targeted population. Methods: A retrospective cross-sectional study was carried out in many teaching hospitals affiliated to the Lebanese University in Lebanon in 2016. Results: The lung cancer incidence was 221.9 per 100000 in 2014. Most patients aged 60 years and over and as regards gender distribution, the majority of them included men. Further, more than half of the patients had the (COPD) and 97% of patients had symptoms at their presentation. Based on the results, 57.9% of them had stage IV lung cancer, but only 12% were diagnosed at the stage IA. Furthermore, 80.6% and 16.4% of patients had non-small and small cell lung cancer, respectively. Finally, 75.4% and 12.1% of them were treated with chemotherapy and underwent surgery, respectively, while 5.2% of patients had radiotherapy. Conclusion: The findings of our study showed a higher incidence rate of lung cancer since 2008 which was diagnosed more commonly in men and with the patient’s history of COPD. Eventually, the diagnosis was mostly made at a later stage with non-small cell lung cancer that was the most common histology type.

Age and gender specific lung cancer incidence and mortality in Hungary: Trends from 2011 through 2016.

e21572 Background: No assessment was conducted describing the age and gender specific epidemiology of lung cancer (LC) prior to 2018 in Hungary, thus the objective of this study was to appraise the detailed epidemiology of lung cancer (ICD-10 C34) in Hungary based on a retrospective analysis of the National Health Insurance Fund database. Methods: This longitudinal study included patients aged ≥20 years with LC diagnosis (ICD-10 C34) between 1st January 2011 and 31th December 2016. Patients with different cancer-related codes 6 months before or 12 months after LC diagnosis or having any anti-cancer treatment different from lung cancer protocols were excluded. Results: In 2011, 4,522 new male lung cancer cases were registered in the NHIF database, while we found 4,176 incident patients in 2016. The number of female patients increased from 2,636 to 2,828 during the same period. The mean age at diagnosis was 64.51 years for men (SD±9.85) and 64.93 years for women (SD±11.19) in 2011, increasing steadily to 65.80 years (SD±9.41) and 65.99 years (SD±10.45), respectively. Lung cancer incidence and mortality increases with age, peaking in the 70–79 age group (375.0/100,000 person-years) among males, while at 60–69 age group for females (148.1/100,000 person-years). The male-to-female incidence rate ratio reached 2.46 to 3.01 (p &lt; 0.0001) among the 70–79 age group. We found 2-11% decrease in male incidence rate at most age groups, while a significant 1-3% increase was observed in older females ( &gt; 60) annually during the study period. Conclusions: This nationwide epidemiology study demonstrated that LC incidence and mortality in Hungary is decreasing in younger male and female population, however we found significant increase of incidence in older female population, similar to international trends. Incidence rates peaked in younger age-groups compared to Western countries, most likely due to higher smoking prevalence in these cohorts, while lower age LC incidence could be attributed to higher competing cardiovascular risk resulting in earlier mortality in smoking population.